In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Outlook Therapeutics Inc (NASDAQ: OTLK) closed at $1.48 in the last session, down -3.90% from day before closing price of $1.54. In other words, the price has decreased by -$3.90 from its previous closing price. On the day, 0.79 million shares were traded. OTLK stock price reached its highest trading level at $1.52 during the session, while it also had its lowest trading level at $1.43.
Ratios:
We take a closer look at OTLK’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.07 and its Current Ratio is at 1.07.
On March 27, 2024, BTIG Research Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $50.
Chardan Capital Markets Upgraded its Neutral to Buy on February 15, 2024, while the target price for the stock was maintained at $3.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 26 ’24 when KENYON LAWRENCE A bought 5,000 shares for $5.69 per share. The transaction valued at 28,446 led to the insider holds 5,946 shares of the business.
Haddadin Yezan Munther bought 1,882 shares of OTLK for $22,242 on Mar 28 ’24. The Director now owns 5,049 shares after completing the transaction at $11.82 per share. On Mar 07 ’24, another insider, Evanson Jeff, who serves as the CHIEF COMMERCIAL OFFICER of the company, bought 62,484 shares for $0.42 each. As a result, the insider paid 26,243 and bolstered with 808,459 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OTLK now has a Market Capitalization of 35010288 and an Enterprise Value of 35710152.
Stock Price History:
Over the past 52 weeks, OTLK has reached a high of $12.85, while it has fallen to a 52-week low of $0.87. The 50-Day Moving Average of the stock is -67.84%, while the 200-Day Moving Average is calculated to be -78.55%.
Shares Statistics:
According to the various share statistics, OTLK traded on average about 1.60M shares per day over the past 3-months and 1771970 shares per day over the past 10 days. A total of 23.41M shares are outstanding, with a floating share count of 15.23M. Insiders hold about 35.60% of the company’s shares, while institutions hold 35.70% stake in the company. Shares short for OTLK as of 1732838400 were 4132323 with a Short Ratio of 2.58, compared to 1730332800 on 3228369. Therefore, it implies a Short% of Shares Outstanding of 4132323 and a Short% of Float of 25.71.
Earnings Estimates
The stock of Outlook Therapeutics Inc (OTLK) is currently being evaluated by 2.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.96, with high estimates of -$0.93 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$3.98 and -$4.04 for the fiscal current year, implying an average EPS of -$4.01. EPS for the following year is -$2.62, with 2.0 analysts recommending between -$2.24 and -$3.01.
